Business Description
BioCryst Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US09058V1035
Share Class Description:
FRA:BO1: Ordinary SharesCompare
Compare
Traded in other countries / regions
BCRX.USABCRX.MexicoBO1.Germany IPO Date
1994-03-03Description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.47 | |||||
| Equity-to-Asset | -0.88 | |||||
| Debt-to-Equity | -1.81 | |||||
| Debt-to-EBITDA | -7.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.29 | |||||
| Beneish M-Score | -3.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 153.4 | |||||
| 3-Year EBITDA Growth Rate | 15.5 | |||||
| 3-Year EPS without NRI Growth Rate | 2.3 | |||||
| 3-Year FCF Growth Rate | 14.6 | |||||
| 3-Year Book Growth Rate | -172.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.82 | |||||
| 9-Day RSI | 40.83 | |||||
| 14-Day RSI | 42.21 | |||||
| 6-1 Month Momentum % | -18.87 | |||||
| 12-1 Month Momentum % | -33.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.31 | |||||
| Quick Ratio | 3.12 | |||||
| Cash Ratio | 2.59 | |||||
| Days Inventory | 2198.07 | |||||
| Days Sales Outstanding | 58.92 | |||||
| Days Payable | 1033.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 | |||||
| Shareholder Yield % | -27.61 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.59 | |||||
| Operating Margin % | -31.29 | |||||
| Net Margin % | -68.36 | |||||
| FCF Margin % | -29.47 | |||||
| ROA % | -43.08 | |||||
| ROIC % | -184.59 | |||||
| ROC (Joel Greenblatt) % | -569.1 | |||||
| ROCE % | -28.03 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.61 | |||||
| EV-to-EBIT | -11.56 | |||||
| EV-to-Forward-EBIT | 65.77 | |||||
| EV-to-EBITDA | -11.72 | |||||
| EV-to-Revenue | 4.12 | |||||
| EV-to-Forward-Revenue | 3.42 | |||||
| EV-to-FCF | -14.02 | |||||
| Price-to-Median-PS-Value | 0.15 | |||||
| Earnings Yield (Greenblatt) % | -8.65 | |||||
| FCF Yield % | -10.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioCryst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 307.304 | ||
| EPS (TTM) (€) | -1.093 | ||
| Beta | 0.37 | ||
| Volatility % | 35.32 | ||
| 14-Day RSI | 42.21 | ||
| 14-Day ATR (€) | 0.162722 | ||
| 20-Day SMA (€) | 4.5251 | ||
| 12-1 Month Momentum % | -33.09 | ||
| 52-Week Range (€) | 4.192 - 8.214 | ||
| Shares Outstanding (Mil) | 206.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioCryst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioCryst Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioCryst Pharmaceuticals Inc Frequently Asked Questions
What is BioCryst Pharmaceuticals Inc(FRA:BO1)'s stock price today?
The current price of FRA:BO1 is €4.25. The 52 week high of FRA:BO1 is €8.21 and 52 week low is €4.19.
When is next earnings date of BioCryst Pharmaceuticals Inc(FRA:BO1)?
The next earnings date of BioCryst Pharmaceuticals Inc(FRA:BO1) is 2024-05-03 Est..
Does BioCryst Pharmaceuticals Inc(FRA:BO1) pay dividends? If so, how much?
BioCryst Pharmaceuticals Inc(FRA:BO1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers